{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:37:09Z","timestamp":1787315829002,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Catatonia, including malignant catatonia, is a severe neuropsychiatric condition historically associated with schizophrenia or schizoaffective disorder. However, recent diagnostic frameworks, such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) and the International Classification of Diseases, 11th Revision (ICD-11), offer a broader understanding. These systems classify catatonia not as a standalone diagnosis but as a specifier that may occur alongside various psychiatric disorders, including schizophrenia spectrum disorders, mood disorders, neurodevelopmental disorders, or medical conditions. Although electroconvulsive therapy (ECT) and benzodiazepines are considered gold standard treatments for catatonia, many healthcare settings lack access to ECT, and certain physical conditions make ECT relatively contraindicated or a high-risk option. Guanfacine, a central adrenergic \u03b12A receptor agonist, has a similar mechanism of action as the sedative dexmedetomidine, which has shown efficacy in treating catatonia. However, the effectiveness of guanfacine in this context has not been tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report five cases of catatonia (including malignant catatonia) associated with schizophrenia or schizoaffective disorder. These cases were treated either in a psychiatric hospital or an outpatient clinic, both of which lacked access to ECT. Extended-release formulation of guanfacine was administered alongside temporary benzodiazepine use, and treatment outcomes were observed. All five patients were in syndromal remission from catatonia following treatment that included guanfacine in combination with other pharmacological interventions. Mild to moderate side effects were observed. These included dizziness and fatigue in one patient, and hypotension and bradycardia in two others. All adverse effects resolved with dose reduction. Complications of catatonia included impaired oral intake requiring nutritional support in two patients and urinary catheterization due to immobility in two patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that guanfacine may serve as a safe and effective alternative to ECT for catatonia in settings where ECT is unavailable or relatively contraindicated. The clinical courses also suggest that dysfunction of the central noradrenergic system may contribute to the pathophysiology of catatonia, and that guanfacine\u2019s selective \u03b12A adrenoceptor modulation may play a role in symptom improvement. Further research is needed to validate these findings and clarify the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07349-3","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:51:00Z","timestamp":1759312260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of five cases of catatonia treated with guanfacine without ECT: a case series from a psychiatric hospital in Japan"],"prefix":"10.1186","volume":"25","author":[{"given":"Hiroki","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amane","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"1","key":"7349_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00534-w","volume":"10","author":"D Hirjak","year":"2024","unstructured":"Hirjak D, Rogers JP, Wolf RC, Kubera KM, Fritze S, Wilson JE, et al. Catatonia. Nat Rev Dis Primers. 2024;10(1):49.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"7349_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1176\/appi.ajp.160.7.1233","volume":"160","author":"MA Taylor","year":"2003","unstructured":"Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160(7):1233\u201341.","journal-title":"Am J Psychiatry"},{"key":"7349_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.schres.2022.09.001","volume":"263","author":"CL Kline","year":"2024","unstructured":"Kline CL, Suzuki T, Simmonite M, Taylor SF. Catatonia is associated with higher rates of negative affect amongst patients with schizophrenia and schizoaffective disorder. Schizophr Res. 2024;263:208\u201313.","journal-title":"Schizophr Res"},{"key":"7349_CR4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text revision; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"7349_CR5","volume-title":"International classification of diseases 11th revision (ICD-11)","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. International classification of diseases 11th revision (ICD-11). Geneva: World Health Organization; 2019."},{"issue":"2","key":"7349_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/08850666221114303","volume":"38","author":"J Connell","year":"2023","unstructured":"Connell J, Oldham M, Pandharipande P, Dittus RS, Wilson A, Mart M, et al. Malignant catatonia: a review for the intensivist. J Intensive Care Med. 2023;38(2):137\u201350.","journal-title":"J Intensive Care Med"},{"issue":"7","key":"7349_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2215-0366(18)30474-7","volume":"6","author":"S Walther","year":"2019","unstructured":"Walther S, Stegmayer K, Wilson JE, Heckers S. Structure and neural mechanisms of catatonia. Lancet Psychiatry. 2019;6(7):610\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"7349_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5498\/wjp.v6.i4.391","volume":"6","author":"SA Rasmussen","year":"2016","unstructured":"Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6(4):391\u20138.","journal-title":"World J Psychiatry"},{"issue":"19","key":"7349_CR9","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJMra2116304","volume":"389","author":"S Heckers","year":"2023","unstructured":"Heckers S, Walther S. Catatonia. N Engl J Med. 2023;389(19):1797\u2013802.","journal-title":"N Engl J Med"},{"issue":"5","key":"7349_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/schbul\/sbx157","volume":"44","author":"M Solmi","year":"2018","unstructured":"Solmi M, Pigato GG, Roiter B, Guaglianone A, Martini L, Fornaro M, et al. Prevalence of catatonia and its moderators in clinical samples: results from a meta-analysis and meta-regression analysis. Schizophr Bull. 2018;44(5):1133\u201350.","journal-title":"Schizophr Bull"},{"issue":"1","key":"7349_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.70051","volume":"4","author":"A Elias","year":"2025","unstructured":"Elias A, Das S, Kirkland J, Loyal S, Thomas N. Safety of electroconvulsive therapy in the context of physiological and medical complexity: a state-of-the-art review. Psychiatry and Clinical Neurosciences Reports. 2025;4(1):e70051.","journal-title":"Psychiatry and Clinical Neurosciences Reports"},{"issue":"1","key":"7349_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0034-7094(12)70110-1","volume":"62","author":"J Afonso","year":"2012","unstructured":"Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012;62(1):118\u201333.","journal-title":"Rev Bras Anestesiol"},{"issue":"5","key":"7349_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1003","volume":"10","author":"RGW Proudman","year":"2022","unstructured":"Proudman RGW, Akinaga J, Baker JG. The signaling and selectivity of \u03b1-adrenoceptor agonists for the human \u03b12A, \u03b12B and \u03b12C-adrenoceptors and comparison with human \u03b11 and \u03b2-adrenoceptors. Pharmacol Res Perspect. 2022;10(5):e01003.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"7349_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.9758\/cpn.2023.21.2.215","volume":"21","author":"CM Smith","year":"2023","unstructured":"Smith CM, Santalucia M, Bunn H, Muzyk A. Sublingual dexmedetomidine for the treatment of agitation in patients with schizophrenia and bipolar disorder. Clin Psychopharmacol Neurosci. 2023;21(2):215\u201321.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"5","key":"7349_CR15","first-page":"20cr02899","volume":"23","author":"M Almeida","year":"2021","unstructured":"Almeida M, Cicolello K, Hanso A, DeCavalcante G, DeOliveira GS. Treatment of acute agitation associated with excited catatonia using dexmedetomidine: case series and literature review. Prim Care Companion CNS Disord. 2021;23(5):20cr02899.","journal-title":"Prim Care Companion CNS Disord"},{"key":"7349_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2024.12.006","author":"S Warn","year":"2025","unstructured":"Warn S, Hwang B, Smith J. Dexmedetomidine in the intensive care unit for extreme aggression in a child with catatonia. J Acad Consult Liaison Psychiatry. 2025. https:\/\/doi.org\/10.1016\/j.jaclp.2024.12.006.","journal-title":"J Acad Consult Liaison Psychiatry"},{"issue":"11","key":"7349_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.clinthera.2013.09.005","volume":"35","author":"SV Faraone","year":"2013","unstructured":"Faraone SV, McBurnett K, Sallee FR, Steeber J, L\u00f3pez FA. Guanfacine extended release: a novel treatment for attention-deficit\/hyperactivity disorder in children and adolescents. Clin Ther. 2013;35(11):1778\u201393.","journal-title":"Clin Ther"},{"issue":"3","key":"7349_CR18","first-page":"107","volume":"44","author":"C Alamo","year":"2016","unstructured":"Alamo C, L\u00f3pez-Mu\u00f1oz F, S\u00e1nchez-Garc\u00eda J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr. 2016;44(3):107\u201312.","journal-title":"Actas Esp Psiquiatr"},{"issue":"8","key":"7349_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084122","volume":"22","author":"K Fukuyama","year":"2021","unstructured":"Fukuyama K, Nakano T, Shiroyama T, Okada M. Chronic administrations of guanfacine on mesocortical catecholaminergic and thalamocortical glutamatergic transmissions. Int J Mol Sci. 2021;22(8):4122.","journal-title":"Int J Mol Sci"},{"key":"7349_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.029","volume":"156","author":"M Okada","year":"2019","unstructured":"Okada M, Fukuyama K, Kawano Y, Shiroyama T, Suzuki D, Ueda Y. Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex. Neuropharmacology. 2019;156:107547.","journal-title":"Neuropharmacology"},{"issue":"10","key":"7349_CR21","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1586\/ern.10.133","volume":"10","author":"AF Arnsten","year":"2010","unstructured":"Arnsten AF. The use of \u03b1-2A adrenergic agonists for the treatment of attention-deficit\/hyperactivity disorder. Expert Rev Neurother. 2010;10(10):1595\u2013605.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"7349_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","volume":"164","author":"JR Strawn","year":"2007","unstructured":"Strawn JR, Keck PE Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870\u20136.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"7349_CR23","doi-asserted-by":"publisher","DOI":"10.36922\/itps.1918","volume":"7","author":"MS Gold","year":"2024","unstructured":"Gold MS, Blum K, Bowirrat A, Pinhasov A, Bagchi D, Dennen CA, et al. A historical perspective on clonidine as an alpha-2A receptor agonist in the treatment of addictive behaviors: focus on opioid dependence. INNOSC Theranostics Pharmacol Sci. 2024;7(3):1918.","journal-title":"INNOSC Theranostics Pharmacol Sci"},{"issue":"1","key":"7349_CR24","first-page":"124","volume":"252","author":"SK Kulkarni","year":"1981","unstructured":"Kulkarni SK. Actions of clonidine on convulsions and behaviour. Arch Int Pharmacodyn Ther. 1981;252(1):124\u201332.","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"5","key":"7349_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/SMJ.0b013e318038fce0","volume":"100","author":"S Taylor","year":"2007","unstructured":"Taylor S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. South Med J. 2007;100(5):494\u20138.","journal-title":"South Med J"},{"issue":"1","key":"7349_CR26","first-page":"19","volume":"16","author":"Z Asztalos","year":"2014","unstructured":"Asztalos Z, Egerv\u00e1ri L, Andr\u00e1ssy G, Faludi G, Frecska E. Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review. Neuropsychopharmacol Hung. 2014;16(1):19\u201328.","journal-title":"Neuropsychopharmacol Hung"},{"issue":"1","key":"7349_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-014-3807-8","volume":"232","author":"FU Lang","year":"2015","unstructured":"Lang FU, Lang S, Becker T, J\u00e4ger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology. 2015;232(1):1\u20135.","journal-title":"Psychopharmacology"},{"key":"7349_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1192\/bjp.161.4.558","volume":"161","author":"DA White","year":"1992","unstructured":"White DA. Catatonia and the neuroleptic malignant syndrome\u2013a single entity? Br J Psychiatry. 1992;161:558\u201360.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"7349_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/NMD.0b013e31827ab24b","volume":"201","author":"F Luchini","year":"2013","unstructured":"Luchini F, Lattanzi L, Bartolommei N, Cosentino L, Litta A, Kansky C, et al. Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis. 2013;201(1):36\u201342.","journal-title":"J Nerv Ment Dis"},{"issue":"7","key":"7349_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1017\/S1092852900013419","volume":"5","author":"DA White","year":"2000","unstructured":"White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr. 2000;5(7):58\u201365.","journal-title":"CNS Spectr"},{"issue":"4","key":"7349_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF02291355","volume":"10","author":"L Gregorakos","year":"2000","unstructured":"Gregorakos L, Thomaides T, Stratouli S, Sakayanni E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res. 2000;10(4):193\u20136.","journal-title":"Clin Auton Res"},{"issue":"2","key":"7349_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.12998\/wjcc.v10.i2.625","volume":"10","author":"CJ Yang","year":"2022","unstructured":"Yang CJ, Chiu CT, Yeh YC, Chao A. Successful management of delirium with dexmedetomidine in a patient with haloperidol-induced neuroleptic malignant syndrome: a case report. World J Clin Cases. 2022;10(2):625\u201330.","journal-title":"World J Clin Cases"},{"issue":"10","key":"7349_CR33","volume":"15","author":"K Maeda","year":"2023","unstructured":"Maeda K, Ichiba T, Kashiwa K, Okazaki Y. Severe recurrence of neuroleptic malignant syndrome: usefulness of dexmedetomidine for antipsychotic withdrawal. Cureus. 2023;15(10):e47088.","journal-title":"Cureus"},{"issue":"3","key":"7349_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","volume":"13","author":"L Tse","year":"2015","unstructured":"Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395\u2013406.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"7349_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/JCP.0000000000001621","volume":"43","author":"FJ Appiani","year":"2023","unstructured":"Appiani FJ, Duarte JM, Saur\u00e9 M, Rodr\u00edguez Cairoli F, Mome\u00f1o V, Yaryour C, et al. Catatonia and delirium: assessment of comorbidity, prevalence, and therapeutic response in medically ill inpatients from a University Hospital. J Clin Psychopharmacol. 2023;43(1):55\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"7349_CR36","first-page":"5","volume":"71","author":"FA Sousa-J\u00fanior","year":"2021","unstructured":"Sousa-J\u00fanior FA, Souza ASR, Lima LC, Santos \u00cdGM, Menezes LAP, Ratis P, et al. Intraoperative clonidine to prevent postoperative emergence delirium following sevoflurane anesthesia in pediatric patients: a randomized clinical trial. Br J Anesthesiol. 2021;71(1):5\u201310.","journal-title":"Br J Anesthesiol"},{"issue":"9","key":"7349_CR37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1164\/rccm.201710-1995OC","volume":"197","author":"Y Skrobik","year":"2018","unstructured":"Skrobik Y, Duprey MS, Hill NS, Devlin JW. Low-dose nocturnal dexmedetomidine prevents ICU delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1147\u201356.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"7349_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.psym.2020.10.003","volume":"62","author":"S Jiang","year":"2021","unstructured":"Jiang S, Czuma R, Cohen-Oram A, Hartney K, Stern TA. Guanfacine for hyperactive delirium: a case series. J Acad Consult Liaison Psychiatry. 2021;62(1):83\u20138.","journal-title":"J Acad Consult Liaison Psychiatry"},{"issue":"1","key":"7349_CR39","volume":"15","author":"S Jiang","year":"2023","unstructured":"Jiang S, Hernandez M, Burke H, Spurling B, Czuma R, Varghese R, et al. A retrospective analysis of guanfacine for the pharmacological management of delirium. Cureus. 2023;15(1):e33393.","journal-title":"Cureus"},{"key":"7349_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2025.05.001","author":"JE Wilson","year":"2025","unstructured":"Wilson JE, Oldham MA, Francis A, Perkey D, Kramer E, Jiang S, et al. Catatonia: American Psychiatric Association resource document. J Acad Consultat Liaison Psychiatry. 2025. https:\/\/doi.org\/10.1016\/j.jaclp.2025.05.001.","journal-title":"J Acad Consultat Liaison Psychiatry"},{"issue":"1","key":"7349_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00441-017-2649-1","volume":"373","author":"EE Benarroch","year":"2018","unstructured":"Benarroch EE. Locus coeruleus. Cell Tissue Res. 2018;373(1):221\u201332.","journal-title":"Cell Tissue Res"},{"issue":"6","key":"7349_CR42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/00000542-199206000-00013","volume":"76","author":"C Correa-Sales","year":"1992","unstructured":"Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology. 1992;76(6):948\u201352.","journal-title":"Anesthesiology"},{"issue":"1","key":"7349_CR43","doi-asserted-by":"publisher","first-page":"9905","DOI":"10.1038\/s41467-024-54395-8","volume":"15","author":"SA Hassani","year":"2024","unstructured":"Hassani SA, Tiesinga P, Womelsdorf T. Noradrenergic alpha-2a receptor stimulation enhances prediction error signaling and updating of attention sets in anterior cingulate cortex and striatum. Nat Commun. 2024;15(1):9905.","journal-title":"Nat Commun"},{"issue":"9","key":"7349_CR44","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0006-3223(99)00139-0","volume":"46","author":"ZM Mao","year":"1999","unstructured":"Mao ZM, Arnsten AF, Li BM. Local infusion of an alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry. 1999;46(9):1259\u201365.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"7349_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","volume":"129","author":"M Wang","year":"2007","unstructured":"Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397\u2013410.","journal-title":"Cell"},{"key":"7349_CR46","doi-asserted-by":"publisher","first-page":"1302718","DOI":"10.3389\/fpsyt.2023.1302718","volume":"14","author":"N Bouaziz","year":"2023","unstructured":"Bouaziz N, Luisada JC, Jabri S, Andrianisaina PS, Bellis A, Januel D. Moving to accelerated protocols of tDCS in catatonia: a case report. Front Psychiatry. 2023;14:1302718.","journal-title":"Front Psychiatry"},{"key":"7349_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.876834","volume":"13","author":"A Haroche","year":"2022","unstructured":"Haroche A, Giraud N, Vinckier F, Amad A, Rogers J, Moyal M, et al. Efficacy of transcranial direct-current stimulation in catatonia: a review and case series. Front Psychiatry. 2022;13:876834.","journal-title":"Front Psychiatry"},{"key":"7349_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2024.111640","volume":"179","author":"L Duque","year":"2024","unstructured":"Duque L, Ghafouri M, Nunez NA, Ospina JP, Philbrick KL, Port JD, et al. Functional neuroimaging in patients with catatonia: a systematic review. J Psychosom Res. 2024;179:111640.","journal-title":"J Psychosom Res"},{"key":"7349_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2020.107327","volume":"176","author":"AFT Arnsten","year":"2020","unstructured":"Arnsten AFT. Guanfacine\u2019s mechanism of action in treating prefrontal cortical disorders: successful translation across species. Neurobiol Learn Mem. 2020;176:107327.","journal-title":"Neurobiol Learn Mem"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07349-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:10:27Z","timestamp":1759317027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07349-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7349"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07349-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective analysis of anonymized clinical cases. As no identifiable data were used and no experimental interventions were involved, formal ethics approval was not required in accordance with standard guidelines for case reports and series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"903"}}